A practical reference on PNB-0408: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-28. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Each osteon consists of concentric layers, or lamellae, of compact bone tissue that surround a central canal, the Haversian canal. The Haversian canal contains the bone's blood supplies. The boundary of an osteon is the cement line. Each Haversian canal is surrounded by varying number (5-20) of concentrically arranged lamellae of bone matrix. Near the surface of the compact bone, the lamellae are arranged parallel to the surface; these are called circumferential lamellae. Some of the osteoblasts develop into osteocytes, each living within its own small space, or lacuna. Osteocytes make contact with the cytoplasmic processes of their counterparts via a network of small transverse canals, or canaliculi. This network facilitates the exchange of nutrients and metabolic waste. Collagen fibers in a particular lamella run parallel to each other, but the orientation of collagen fibers within other lamellae is oblique. The collagen fiber density is lowest at the seams between lamellae, accounting for the distinctive microscopic appearance of a transverse section of osteons. The space between osteons is occupied by interstitial lamellae, which are the remnants of osteons that were partially resorbed during the process of bone remodeling. Osteons are connected to each other and the periosteum by oblique channels called Volkmann's canals or perforating canals.
On August 29, 1949, the Soviet Union tested its first nuclear weapon at Semipalatinsk in Kazakhstan (see also Soviet atomic bomb project). Scientists in the United States from the Manhattan Project had warned that, in time, the Soviet Union would certainly develop nuclear capabilities of its own. Nevertheless, the effect upon military thinking and planning in the United States was dramatic, primarily because American military strategists had not anticipated the Soviets would "catch up" so soon. However, at this time, they had not discovered that the Soviets had conducted significant nuclear espionage of the project from spies at Los Alamos National Laboratory, the most significant of which was done by the theoretical physicist Klaus Fuchs. The first Soviet bomb was more or less a deliberate copy of the Fat Man plutonium device. In the same year the first US-Soviet nuclear war plan was penned in the US with Operation Dropshot. With the monopoly over nuclear technology broken, worldwide nuclear proliferation accelerated. The United Kingdom tested its first independent atomic bomb in 1952, followed by France developing its first atomic bomb in 1960 and then China developing its first atomic bomb in 1964. While much smaller than the arsenals of the United States and the Soviet Union, Western Europe's nuclear reserves were nevertheless a significant factor in strategic planning during the Cold War.
Becker muscular dystrophy has adult-onset exercise-induced muscle cramping, pain, and elevated CK. Tubular aggregate myopathy (TAM) types 1 and 2 has exercise-induced muscle pain, fatigue, stiffness, with proximal muscle weakness and calf muscle pseudohypertrophy. TAM1 has cramping at rest, while TAM2 has cramping during exercise. Stormorken syndrome includes the symptoms of TAM, but is a more severe presentation including short stature and other abnormalities. Satoyoshi syndrome has exercise-induced painful muscle cramps, muscle hypertrophy, and short stature. Dimethylglycine dehydrogenase deficiency has muscle fatigue, elevated CK, and fishy body odour. Myopathy with myalgia, increased serum creatine kinase, with or without episodic rhabdomyolysis (MMCKR) has exercise-induced muscle cramps, pain, and fatigue; with some exhibiting proximal muscle weakness.
Different amino-acid sequences have different propensities for forming α-helical structure. Alanine, uncharged glutamate, leucine, charged arginine, methionine and charged lysine have especially high helix-forming propensities, whereas proline and glycine have poor helix-forming propensities. Proline either breaks or kinks a helix, both because it cannot donate an amide hydrogen bond (because it has none) and because its sidechain interferes sterically with the backbone of the preceding turn – inside a helix, which forces a bend of about 30° in the helix's axis. However, proline is often the first residue of a helix, presumably due to its structural rigidity. At the other extreme, glycine also tends to disrupt helices because its high conformational flexibility makes it entropically expensive to adopt the relatively constrained α-helical structure.
Sources: en.wikipedia.org
=== Dosage units === One international unit of insulin (1 IU) is defined as the "biological equivalent" of 34.7 μg pure crystalline insulin. The first definition of a unit of insulin was the amount required to induce hypoglycemia in a rabbit. This was set by James Collip at the University of Toronto in 1922. Of course, this was dependent on the size and diet of the rabbits. The unit of insulin was set by the insulin committee at the University of Toronto. The unit evolved eventually to the old USP insulin unit, where one unit (U) of insulin was set equal to the amount of insulin required to reduce the concentration of blood glucose in a fasting rabbit to 45 m g/d L (2.5 m mol/L). Once the chemical structure and mass of insulin was known, the unit of insulin was defined by the mass of pure crystalline insulin required to obtain the USP unit. The unit of measurement used in insulin therapy is not part of the International System of Units (abbreviated SI) which is the modern form of the metric system. Instead the pharmacological international unit (IU) is defined by the WHO Expert Committee on Biological Standardization.
Odd-chain fatty acids can be oxidized to yield acetyl-CoA and propionyl-CoA, the latter serving as a precursor to succinyl-CoA, which can be converted to oxaloacetate and enter into gluconeogenesis. In contrast, even-chain fatty acids are oxidized to yield only acetyl-CoA, whose entry into gluconeogenesis requires the presence of a glyoxylate cycle (also known as glyoxylate shunt) to produce four-carbon dicarboxylic acid precursors. The glyoxylate shunt comprises two enzymes, malate synthase and isocitrate lyase, and is present in fungi, plants, and bacteria. Despite some reports of glyoxylate shunt enzymatic activities detected in animal tissues, genes encoding both enzymatic functions have only been found in nematodes, in which they exist as a single bi-functional enzyme. Genes coding for malate synthase alone (but not isocitrate lyase) have been identified in other animals including arthropods, echinoderms, and even some vertebrates. Mammals found to possess the malate synthase gene include monotremes (platypus) and marsupials (opossum), but not placental mammals. The existence of the glyoxylate cycle in humans has not been established, and it is widely held that fatty acids cannot be converted to glucose in humans directly. Carbon-14 has been shown to end up in glucose when it is supplied in fatty acids, but this can be expected from the incorporation of labelled atoms derived from acetyl-CoA into citric acid cycle intermediates which are interchangeable with those derived from other physiological sources, such as glucogenic amino acids.
== History == Marc Wilkins coined the term proteome in 1994 in a symposium on "2D Electrophoresis: from protein maps to genomes" held in Siena in Italy. It appeared in print in 1995, with the publication of part of his PhD thesis. Wilkins used the term to describe the entire complement of proteins expressed by a genome, cell, tissue or organism.
Sources: en.wikipedia.org
1% w/v BCA-Na2 (CAS: 979-88-4) 2% w/v Na2CO3·H2O (CAS: 5968-11-6) 0.16% w/v Na2 tartrate (CAS: 868-18-8) 0.4% w/v NaOH (CAS: 1310-73-2) 0.95% w/v NaHCO3 (CAS: 144-55-8) Add 50% NaOH or solid NaHCO3 to adjust the pH to 11.25 A suggested but untested alternative formulation in the Smith manuscript is to leave out the NaOH (and presumably not perform the manual pH adjustment to 11.25), but instead to dissolve the other components in a preprepared buffer of 0.25 M Na2CO3 and 0.01 M NaHCO3. Notably, Smith synthesized their own BCA via the Pfitzinger reaction of isatin and acetoin, substituting NaOH for KOH but otherwise following the synthetic method of Lesene and Henze, as the BCA available from commercial vendors of that time was too impure for their use. At least three successive recrystallizations of their synthesized BCA from 70˚C water was needed to sufficiently purify it for the assay. Reagent B
=== Old model of coloration with four primaries === The ancient Greeks, under the influence of Aristotle, Democritus and Plato, considered that there were four basic colors that coincided with the four elements: earth (ochre), sky (blue), water (green) and fire (red), while black and white represented the light of day and the darkness of night. The four-color system is formed by the primaries yellow, green, blue and red, and was supported by Alberti in his "De Pictura" (1436), using the rectangle, rhombus, and color wheel to represent them.
The liver is a vital organ and supports almost every other organ in the body. Severe or end-stage liver failure has dire consequences for the body's overall health and quality of life. Visible signs of liver disease include jaundice and ascites. Hepatomegaly refers to an enlarged liver and may be caused by several underlying diseases. It can be palpated in an abdominal exam. Scarring (fibrosis) of the liver from any cause can lead to cirrhosis. Cirrhosis increases the resistance to blood flow in the liver, and can result in portal hypertension. Congested anastomoses between the portal venous system and the systemic circulation, can be a subsequent condition. The most common chronic liver disease is nonalcoholic fatty liver disease, which affects an estimated one-third of the world population. Hepatitis is a common condition of inflammation of the liver. The cause is usually viral, and the most common of these infections are hepatitis A, B, C, D, and E. Some of these infections are transmitted sexually or through non-sterile needles. Inflammation can also be caused by other viruses in the family Herpesviridae such as the herpes simplex virus. Chronic (rather than acute) infection with hepatitis B virus or hepatitis C virus is the main cause of liver cancer. Globally, about 248 million individuals are chronically infected with hepatitis B (with 843,724 in the U.S.), and 142 million are chronically infected with hepatitis C (with 2.7 million in the U.S.).
radioactive decay The process by which an unstable atomic nucleus loses excess nuclear energy by emitting radiation in any of several forms, including as gamma radiation, as alpha or beta particles, or by ejecting electrons from its atomic orbitals.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.